Lapatinib-incorporated lipoprotein-like nanoparticles: Preparation and a proposed breast cancer-targeting mechanism

Acta Pharmacologica Sinica

Volumn 35, Issue 6, 2014, Pages 846-852

  Zhang, Li ^b   Zhang, Shuang ^c   Ruan, Shao Bo ^a   Zhang, Qian Yu ^a   He, Qin ^a   Gao, Hui Le ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

breast cancer; cell arrest; drug delivery; drug targeting; EGFR; endosome; HER2; Lapatinib; nanoparticle

Indexed keywords

LAPATINIB; LIPOPROTEIN LIKE NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; LIPOPROTEIN; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC FORCE MICROSCOPY; BREAST CANCER; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; MOUSE; NONHUMAN; PARTICLE SIZE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HUMAN; METABOLISM; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIPOPROTEINS; MICE; MICE, SCID; NANOPARTICLES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84902241201     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2014.26     Document Type: Article

References (23)

1. Moreira C,Kaklamani V. Lapatinib and breast cancer: current indications and outlook for the future, Expert Rev Anticancer Ther, 2010, 10,1171-82.
2. Medina PJ, Goodin S. Lapat inib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008; 30: 1426-47.
3. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005; 353: 1652-54.
4. LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, et al. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the h istone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res 2011; 71: 3635-48.
5. Gao H, Yang Z, Cao S, Xi Z, Zhang S, Pang Z, et al. Behavior and antiglioma eff ect of lapatinib-incorporated lipoprotein-like nanoparticles. Nanotechnology 2012; 23: 435101.
6. Olaussen KA, Commo F, Tailler M, Lacroix L, Vitale I, Raza SQ, et al. Synergistic pro apoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. Oncogene 2009; 28: 4249-60.
7. Gao H, Cao S, Chen C, Cao S, Yang Z, Pang Z, et al. Incorporation of lapatinib into lipoprotein-like nanoparticles with enhanced water solubility and anti-tumor effect in breast cancer. Nanomedicine (Lond) 2013; 8: 1429-42.
8. Heikkila JE, Vaha-Ko skela MJ, Ruotsalainen JJ, Martikainen MW, Stanford MM, McCart JA, et al. Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PLoS One 2010; 5: e8603.
9. Gao H, Pan S, Yang Z, Cao S, Chen C, Jiang X, et al. A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. Biomateri als 2011; 32: 8669-75.
10. Gao H, Wang Y, Chen C, Chen J, We Y, Cao S, et al. Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug. Int J Pharm 2014; 461: 478-88.
11. Liu J, Shapiro JI. Endocytosis and signal transduction: basic science update. Biol Res Nurs 2003; 5: 117-28.
12. Gao H, Yang Z, Zhang S, Cao S, Shen S, Pang Z, et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep 2013; 3: 2534.
13. Lu W, Sun Q, Wan J, She Z, Jiang XG. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res 2006; 66: 11878-87.
14. Zhang LM, Zhang JN, Yang SW, Dong C, Fang DD, Li J, et al. Expression of HER2 in glioma cell lines A172, U251, U87 and SHG-44 and its significance. Chin J Neurosurg Dis Res 2011; 10: 151 -53.
15. Barenholz Y. Doxil® -The first FDA-approved nano-drug: Lessons learned. J Control Release 2012; 160: 117-34.
16. Gao H, Pang Z, Pan S, Cao S, Yang Z, Chen C, et al. Anti-glioma effect and safety of docetaxel-loaded nanoemulsion. Arch Pharm Res 2012; 35: 333-41.
17. Gao H, Pang Z, Jiang X. Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Pharm Res 2013; 30: 2485-98.
18. Mahmoudi M, Azadmanesh K, Shokrgozar MA, Journeay WS, Laurent S. Effect of nanoparticles on the cell life cycle. Chem Rev 2011; 111: 3407-32.
19. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001; 46: 169-85.
20. Matsum ura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-92.
21. T orchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 2010; (197): 3-53.
22. Fang J,Sawa T,Maeda H. Factors and mechanism of " EPR" eff ect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol,2003, 519, 29-49.
23. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998; 95: 4607-12.